Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Pediatric Nephrology
Erschienen in: Pediatric Nephrology 6/2007

01.06.2007 | Brief Report

Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?

verfasst von: Graham C. Smith

Erschienen in: Pediatric Nephrology | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

We each have nephrotic patients who become steroid dependent and in whom multiple immunosuppressive agents are employed. There is a need to balance possible therapeutic benefits with drug toxicity. This case report describes such a patient, who has suffered from nephrotic syndrome for over 11 years and had become resistant to the usual therapies. He was therefore given a single dose of the anti-CD20 drug rituximab, to which he showed a prompt response, leaving him free of proteinuria for the past 10 months.
Literatur
1.
Sharma M, Sharma R, McCarthy ET, Savin VJ (1999) ‘The FSGS factor’: enrichment and in vivo effect of activity from focal segmental glomerulosclerosis factor. J Am Soc Nephrol 10:552–561PubMed
2.
Artero ML, Sharma R, Savin VJ, Vincenti F (1994) Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 23:574–581PubMed
3.
Tanaka R, Yoshikawa N, Nakamura H, Ito H (1992) Infusion of peripheral blood mononuclear cell products from nephrotic children increases albuminuria in rats. Nephron 60:35–41
4.
Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M (1991) A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 40:453–460PubMed
5.
Couser W, Badger A, Cooperband S, Stilmand M, Jermanovich N, Aurora S, Doner D, Schmitt G (1977) Hodgkin’s disease and lipoid nephrosis. Lancet i:912–913
6.
Belghiti D, Vernant JP, Hirbec G, Gubler MC, Andre C, Sobel A (1981) Nephrotic syndrome associated with T-cell lymphoma. Cancer 47:1878–1882PubMed
7.
McDonald P, Kalra PA, Coward RA (1992) Thymoma and minimal-change glomerulonephritis. Nephrol Dial Transplant 7:357–359PubMed
8.
Hardwicke J, Soothill J, Squire J, Holti G (1959) Nephrotic syndrome associated with pollen hypersensitivity. Lancet i:450
9.
Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Jacques Y, Hurault de Ligny B, Niaudet P, Charpentier B, Soulillou JP (1994) Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 330:7–14PubMed
10.
Dantal J, Godfrin Y, Koll R, Perretto S, Naulet J, Bouhours JF, Soulillou JP (1998) Antihuman immunoglobulin affinity immunoabsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol 9:1709–1715PubMed
11.
Szeto C, Gillespie KM, Mathieson PW (2000) Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance. Immunology 100:217–224PubMedPubMedCentral
12.
Kimata H, Fujimoto M, Furusho K (1995) Involvement of interleukin (IL)-13, but not IL-4, in spontaneous IgE and IgG4 production in nephrotic syndrome. Eur J Immunol 25:1497–1501PubMed
13.
Yap HK, Cheung W, Murugasu B, Sim SK, Seah CC, Jordan SC (1999) Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 10:529–537PubMed
14.
Kemper MJ, Meyer-Jark T, Lilova M, Muller-Wiefel DE (2003) Combined B- and T-cell activation in childhood steroid-sensitive nephrotic syndrome. Clin Nephrol 60:242–247PubMed
15.
Benz K, Dötsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after Rituximab therapy. Pediatr Nephrol 19:794–797PubMed
16.
Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M (2005) Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 20:1660–1663
17.
Pescovitz MD, Book BK, Sidner RA (2006) Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 354:1961–1963PubMed
18.
Gilbert RD, Rigden SPA (2006) Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol 21:1698–1700PubMed
19.
Westphal S, Hansson S, Mjörnstedt L, Mölne J, Swerkersson S, Friman S (2006) Early recurrence nephrotic syndrome (immunoglobulin M nephropathy) after renal transplantation successfully treated with combinations of plasma exchange, immunoglobulin, and rituximab. Transplant Proc 38:2659–2660PubMed
20.
Kemper MJ, Möller K, Ludwig K, Rink N, Müller-Wiefel (2006) Rituximab (RTX) in the treatment of refractory steroid sensitive nephrotic syndrome (abstract). Pediatr Nephrol 21:1528
21.
Dallochio IA, Trimoreau F, Feuillard J, Guigonis V (2006) A case of steroid-dependent nephrotic syndrome treated with rituximab (abstract). Pediatr Nephrol 21:1615
22.
Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Newman RA, Hanna N, Anderson DR (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445PubMed
23.
Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J (2003) In vitro mechanisms of action of Rituximab on primary non-Hodgkins lymphomas. Blood 101:949–954PubMed
24.
Maloney DG, Smith B, Rose A (2002) Rituximab: mechanism of action and resistance. Semin Oncol 29 [Suppl 2]:2–9PubMed
25.
Robak T (2004) Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 72:79–88PubMed
26.
Raj A, Bertolone S, Cheerva A (2004) Successful treatment of refractory autoimmune hemolytic anemia with monthly Rituximab following nonmyeloablative stem cell transplantation for sickle cell disease. J Pediatr Hematol Oncol 26:312–314PubMed
27.
Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, Jankovic M, Pierani P, De Stefano P, Bonora MR, Locatelli F (2003) Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101:3857–3861PubMed
28.
Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A (2001) Treatment of childhood autoimmune haemolytic anaemia with Rituximab. Lancet 358:1511–1513PubMed
29.
Saleh MN, Gutheil J, Moore M, Bunch PW, Butler J, Kunkel L, Grillo-Lopez AJ, LoBuglio AF (2000) A pilot study of the anti-CD20 monoclonal antibody Rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 27:99–103PubMed
30.
Stasi R, Pagano A, Stipa E, Amadori S (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98:952–957PubMed
31.
Zaja F, Vianelli N, Sperotto A, De Vita S, Iacona I, Zaccaria A, Masolini P, Tomadini V, Tani M, Molinari AL, Baccarani M, Fanin R (2003) B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 88:538–546PubMed
32.
Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125:232–239PubMed
33.
Levine TD, Pestronk A (1999) IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 52:1701–1704PubMed
34.
Pestronk A, Florence J, Miller T, Choksi R, Al Lozi MT, Levine TD (2003) Treatment of IgM antibody associated polyneuropathies using Rituximab. J Neurol Neurosurg Psychiatry 74:485–489PubMedPubMedCentral
35.
Rojas-Garcia R, Gallardo E, de Andres I, de Luna N, Juarez C, Sanchez P, Illa I (2003) Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to Rituximab. Neurology 61:1814–1816PubMed
36.
Renaud S, Gregor M, Fuhr P, Lorenz D, Deuschl G, Gratwohl A, Steck AJ (2003) Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 27:611–615PubMed
37.
Nobile-Orazio E (2004) IgM paraproteinaemic neuropathies. Curr Opin Neurol 17:599–605PubMed
38.
Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI, Weksler BB, Schechter GP (2002) Rituximab in the treatment of acquired factor VIII inhibitors. Blood 100:3426–3428PubMed
39.
Keogh KA, Wylam ME, Stone JH, Specks U (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody associated vasculitis. Arthritis Rheum 52:262–268PubMed
40.
Eriksson P (2005) Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with Rituximab. J Intern Med 257:540–548PubMed
41.
Stahl HD, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Edwards JCW, Clase DR, Stevens RM, Shaw TM (2003) Rituximab in rheumatoid arthritis: efficacy and safety from a randomized controlled trial. Ann Rheum Dis 62 [Suppl]:0P004
42.
Shaw T, Quan J, Totoritis MC (2003) B cell therapy for rheumatoid arthritis: the Rituximab (anti-CD20) experience. Ann Rheum Dis 62 [Suppl 2]:ii55–ii59PubMedPubMedCentral
43.
Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581PubMed
44.
DeVita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G (2002) Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 46:2029–2033
45.
Tuscano JM (2002) Successful treatment of infliximab-refractory rheumatoid arthritis with Rituximab. Arthritis Rheum 46:3420
46.
Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA (2002) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46:2673–2677PubMed
47.
Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ (2003) The relationship of FcγRIIIa genotype to degree of B cell depletion by Rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48:455–459PubMed
48.
Eisenberg R (2003) Mechanisms of autoimmunity. Immunol Res 27:203–218PubMed
49.
Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of Rituximab. Arthritis Rheum 50:2580–2589PubMed
50.
Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, Tullus K (2005) B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52:3168–3174PubMed
51.
52.
Martin F, Chan AC (2004) Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 20:517–527PubMed
53.
54.
Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA (2004) B lymphocyte depletion in the treatment of systemic lupus erythematosus. Arthritis Rheum 50:S447
Metadaten
Titel
Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?
verfasst von
Graham C. Smith
Publikationsdatum
01.06.2007
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 6/2007
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-006-0427-5

Weitere Artikel der Ausgabe 6/2007

Pediatric Nephrology 6/2007 Zur Ausgabe

Educational Feature

Embryology and genetics of primary vesico-ureteric reflux and associated renal dysplasia

Brief Report

Plasma exchange combined with immunosuppressive treatment in a child with rapidly progressive IgA nephropathy

Original Article

Sulfasalazine reduces inflammatory renal injury in unilateral ureteral obstruction

Brief Report

Etiology of nephrocalcinosis in northern Indian children

Original Article

The malnutrition and inflammation axis in pediatric patients with chronic kidney disease

Original Article

Renal and urologic manifestations of pediatric condition falsification/Munchausen by proxy

Neu im Fachgebiet Pädiatrie

Ähnliche Überlebensraten nach Reanimation während des Transports bzw. vor Ort

29.05.2024 Reanimation im Kindesalter Nachrichten

Laut einer Studie aus den USA und Kanada scheint es bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

24.05.2024 Pränatale und perinatale Diagnostik Nachrichten

Ob ungeborene Kinder, die kleiner als die meisten Gleichaltrigen sind, schneller wachsen, wenn die Mutter sich mehr ausruht, wird diskutiert. Die Ergebnisse einer US-Studie sprechen dafür.

Bei Amblyopie früher abkleben als bisher empfohlen?

22.05.2024 Fehlsichtigkeit Nachrichten

Bei Amblyopie ist das frühzeitige Abkleben des kontralateralen Auges in den meisten Fällen wohl effektiver als der Therapiestandard mit zunächst mehrmonatigem Brilletragen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise